MCID: NNL002
MIFTS: 54

Nonalcoholic Steatohepatitis

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

MalaCards integrated aliases for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 54 74
Non-Alcoholic Steatohepatitis 54 17
Non-Alcoholic Fatty Liver Disease 54
Nash 54

Classifications:



External Ids:

UMLS 74 C3241937

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 54 Nonalcoholic steatohepatitis, or NASH, is a common, often �??silent�?� liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. NASH most often occurs in people who are middle aged and overweight or obese. Affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. Treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. The underlying cause of NASH remains unclear.

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic steatohepatitis, is related to nonalcoholic fatty liver disease and hepatitis. An important gene associated with Nonalcoholic Steatohepatitis is SQSTM1 (Sequestosome 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Developmental Biology. The drugs Ezetimibe and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 77 Non-alcoholic fatty liver disease (NAFLD) is excessive fat build-up in the liver due to causes other... more...

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 nonalcoholic fatty liver disease 32.3 ADIPOQ INS KRT18 LEP PNPLA3
2 hepatitis 31.1 GPT KRT18 SLC17A5 TNF
3 hepatitis c 31.1 GPT KRT18 TNF
4 fatty liver disease 31.0 ADIPOQ CYP2E1 INS LEP PNPLA3 PPARA
5 arteries, anomalies of 30.9 ADIPOQ INS LEP TNF
6 glucose intolerance 30.7 ADIPOQ INS LEP
7 hemosiderosis 30.7 GPT HFE
8 cryptogenic cirrhosis 30.7 HFE KRT18
9 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.7 ADIPOQ INS
10 infantile liver failure syndrome 1 30.6 GPT SLC17A5
11 hepatitis b 30.6 GPT SLC17A5 TNF
12 gestational diabetes 30.6 ADIPOQ INS LEP
13 sleep apnea 30.5 ADIPOQ INS LEP TNF
14 lipodystrophy, familial partial, type 2 30.4 INS LEP
15 chronic kidney failure 30.3 ADIPOQ INS LEP
16 prader-willi syndrome 30.3 ADIPOQ INS LEP
17 burns 30.2 INS TNF
18 hyperglycemia 30.2 ADIPOQ INS LEP
19 apnea, obstructive sleep 30.2 ADIPOQ INS LEP TNF
20 acanthosis nigricans 30.2 ADIPOQ INS LEP
21 acute liver failure 30.1 GPT SLC17A5
22 alcoholic hepatitis 30.1 CYP2E1 GPT KRT18 SLC17A5 TNF
23 lipid metabolism disorder 30.0 ADIPOQ INS LEP PPARA
24 diabetes mellitus, noninsulin-dependent 29.9 ADIPOQ GPT INS LEP PPARA SLC17A5
25 arteriosclerosis 29.8 ADIPOQ INS PPARA
26 alcoholic liver cirrhosis 29.7 CYP2E1 PNPLA3 SLC17A5
27 viral hepatitis 29.6 GPT HFE KRT18 SLC17A5 TNF
28 liver cirrhosis 29.6 ADIPOQ CYP2E1 GPT HFE KRT18 LEP
29 diabetes mellitus 29.6 ADIPOQ HFE INS LEP PPARA TNF
30 atherosclerosis susceptibility 29.6 ADIPOQ INS PPARA TNF
31 fatty liver disease, nonalcoholic 1 29.3 ADIPOQ GPT INS KRT18 LEP PPARA
32 overnutrition 29.0 ADIPOQ INS LEP PPARA TNF
33 liver disease 28.5 ADIPOQ CYP2E1 GPT HFE INS KRT18
34 body mass index quantitative trait locus 11 28.5 ADIPOQ CYP2E1 GPT INS LEP PNPLA3
35 hepatocellular carcinoma 10.9
36 coronary artery anomaly 10.6
37 hepatitis c virus 10.5
38 heart disease 10.5
39 fish-eye disease 10.4
40 hypertension, essential 10.4
41 helicobacter pylori infection 10.4
42 inflammatory bowel disease 10.4
43 adult dermatomyositis 10.3 GPT TNF
44 paraquat poisoning 10.3 GPT SLC17A5
45 leptin deficiency or dysfunction 10.3
46 pyridoxine deficiency 10.3 GPT SLC17A5
47 opisthorchiasis 10.3 GPT TNF
48 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.3 INS LEP
49 prostatic hyperplasia, benign 10.3
50 bone mineral density quantitative trait locus 3 10.3

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 ADIPOQ CYP2E1 HFE INS LEP SLC17A5
2 growth/size/body region MP:0005378 10.02 ADIPOQ HFE INS KRT18 LEP PPARA
3 homeostasis/metabolism MP:0005376 10.02 ADIPOQ CYP2E1 HFE INS LEP PNPLA3
4 cellular MP:0005384 10.01 ADIPOQ HFE INS LEP PPARA SLC17A5
5 adipose tissue MP:0005375 10 ADIPOQ INS LEP PNPLA3 PPARA SQSTM1
6 liver/biliary system MP:0005370 9.85 ADIPOQ CYP2E1 HFE INS KRT18 LEP
7 integument MP:0010771 9.73 ADIPOQ INS LEP PPARA SQSTM1 TNF
8 mortality/aging MP:0010768 9.65 ADIPOQ CYP2E1 HFE INS KRT18 LEP
9 skeleton MP:0005390 9.17 ADIPOQ GPT HFE INS LEP SQSTM1

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 285)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
2
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
3
Empagliflozin Approved Phase 4 864070-44-0
4
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
5
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
6
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
7
Ribavirin Approved Phase 4,Not Applicable 36791-04-5 37542
8
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
9
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
10
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
12
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
13
Rifaximin Approved, Investigational Phase 4,Not Applicable 80621-81-4 46783403 6436173
14
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
15
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
16
Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
17
Alogliptin Approved Phase 4 850649-61-5 11450633
18
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 59-02-9 14985
19
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
21 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Not Applicable 6829-55-6
22 Anticholesteremic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 HIV Integrase Inhibitors Phase 4
29 Anti-HIV Agents Phase 4,Phase 3,Phase 2
30 Integrase Inhibitors Phase 4
31 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antiviral Agents Phase 4,Phase 3,Phase 2,Not Applicable
33 Raltegravir Potassium Phase 4
34 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Sodium-Glucose Transporter 2 Inhibitors Phase 4,Phase 3,Phase 1
36 Tocopherols Phase 4,Phase 3,Phase 2,Not Applicable
37 Tocotrienols Phase 4,Phase 3,Phase 2,Not Applicable
38 insulin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Antioxidants Phase 4,Phase 3,Phase 2,Not Applicable
44 Trace Elements Phase 4,Phase 3,Phase 2,Not Applicable
45 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Vitamins Phase 4,Phase 3,Phase 2,Not Applicable
47 Nutrients Phase 4,Phase 3,Phase 2,Not Applicable
48 Micronutrients Phase 4,Phase 3,Phase 2,Not Applicable
49 Interferon-alpha Phase 4,Not Applicable
50 Interferon alpha-2 Phase 4,Not Applicable

Interventional clinical trials:

(show top 50) (show all 377)
# Name Status NCT ID Phase Drugs
1 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
2 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
3 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
4 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
5 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
6 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
7 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
8 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
9 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
10 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
11 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
12 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
13 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
14 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Recruiting NCT03198572 Phase 4 Placebo;Berberine
15 To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 Diabetes Not yet recruiting NCT03950505 Phase 4 Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks
16 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg
17 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
18 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
19 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
20 Regression of Fatty Heart by Valsartan Therapy Withdrawn NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
21 Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01623024 Phase 3 Vitamin D
22 The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver Unknown status NCT02530138 Phase 2, Phase 3
23 Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores Unknown status NCT00658164 Phase 3
24 To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites Unknown status NCT02649335 Phase 3 Propranolol
25 Metformin in Non-Alcoholic Fatty Liver Disease Unknown status NCT00303537 Phase 2, Phase 3 metformin
26 The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT01791959 Phase 2, Phase 3
27 Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis Completed NCT00820651 Phase 3
28 Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH) Completed NCT00681408 Phase 2, Phase 3 Omega 3 Fish Oil supplements;Placebo
29 Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed NCT03053063 Phase 3 SEL;Placebo
30 Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) Completed NCT00063622 Phase 3 Pioglitazone;Matching placebo
31 Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis Completed NCT00509418 Phase 3
32 Anti-Fibrotic Effects of Losartan In Nash Evaluation Study Completed NCT01051219 Phase 3 Losartan
33 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed NCT00267670 Phase 2, Phase 3 Pentoxifylline;Placebo
34 S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis Completed NCT00108589 Phase 3 S-adenosylmethionine
35 Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Completed NCT01934777 Phase 3 Docosahexaenoic Acid plus Vitamin E plus choline;placebo pearls
36 The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Completed NCT02030977 Phase 2, Phase 3
37 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed NCT02279524 Phase 2, Phase 3 Aramchol
38 The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Completed NCT02395900 Phase 2, Phase 3
39 Omega 3 Supplementation in Fatty Liver Completed NCT01992809 Phase 3
40 Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Completed NCT00063635 Phase 3 Metformin;Matching placebo
41 Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group Completed NCT01754714 Phase 3 SAMe 1000 mg;SAMe 1500 mg;SAMe 2000 mg
42 DHA and Vitamin D in Children With Biopsy-proven NAFLD Completed NCT02098317 Phase 3 DHA plus Vitamin D;Placebo
43 Prevention of Cardiovascular Disease Using a Single PolyPill in an Urban Population - Focus on Liver-Related Variables. Completed NCT01245608 Phase 3 Polypill
44 Development of a Breath Test for Monitoring Patients With Liver Disease Completed NCT00244569 Phase 3 13C-Methacetin
45 Role of Exenatide in NASH-a Pilot Study Completed NCT00650546 Phase 2, Phase 3 Exenatide
46 Hydroxytyrosol and Vitamin E in Pediatric NASH Completed NCT02842567 Phase 3 Hydroxytyrosol plus Vitamin E;Placebo
47 Replacement GH Therapy After Bariatric Surgery in Patients With Very Severe Obesity Completed NCT00553852 Phase 3 Recombinant GH Saizen (Merck-Serono)
48 Targeting Inflammation Using Salsalate in CardioVascular Disease Completed NCT00624923 Phase 2, Phase 3 Salsalate;Placebo
49 Effect of Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Completed NCT00655018 Phase 2, Phase 3
50 Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Completed NCT01371825 Phase 2, Phase 3 Sebelipase alfa (SBC-102)

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

42
Liver, Testes, Kidney, Endothelial, Bone, Neutrophil, Spleen

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 2894)
# Title Authors Year
1
Risk of atrial fibrillation in patients with nonalcoholic steatohepatitis. ( 31020773 )
2019
2
Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. ( 30877708 )
2019
3
Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus? ( 30847693 )
2019
4
Letter: Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. ( 30819009 )
2019
5
Response: Letter: Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. ( 30821517 )
2019
6
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. ( 30684076 )
2019
7
Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. ( 31086120 )
2019
8
PROs of Patient-reported Outcomes for Nonalcoholic Fatty Liver Disease and Effects on Treatment for Nonalcoholic Steatohepatitis. ( 30981002 )
2019
9
Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. ( 31011302 )
2019
10
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). ( 31036494 )
2019
11
Author Correction: A comprehensive bioinformatics analysis on multiple Gene Expression Omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 31053720 )
2019
12
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in HIV infection: a metabolic approach of an infectious disease. ( 30905208 )
2019
13
Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. ( 30762163 )
2019
14
Metformin for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. ( 30763050 )
2019
15
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. ( 30482910 )
2019
16
Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. ( 30335697 )
2019
17
Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma. ( 30959469 )
2019
18
Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. ( 30908822 )
2019
19
The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis. ( 30765939 )
2019
20
Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy. ( 30210131 )
2019
21
Nonalcoholic steatohepatitis and hepatocellular carcinoma: crying wolf or promoting healthy living? ( 31004760 )
2019
22
A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC). ( 30958566 )
2019
23
Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. ( 30970564 )
2019
24
High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. ( 30320609 )
2019
25
Chronic intermittent hypoxia accelerates liver fibrosis in rats with combined hypoxia and nonalcoholic steatohepatitis via angiogenesis rather than endoplasmic reticulum stress. ( 30668625 )
2019
26
The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. ( 30593409 )
2019
27
The role of endothelial dysfunction in the progression mechanisms of non-alcoholic steatohepatitis in patients with obesity and chronic kidney disease. ( 31055525 )
2019
28
Biochemical and molecular-genetic indicators of inflammation and apoptosis in liver cirrhosis as an outcome of the progression of non-alcoholic steatohepatitis. ( 31094472 )
2019
29
Increased Risk of Death in First Year After Liver Transplantation Among Patients with Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies. ( 31004758 )
2019
30
Validation of Chronic Liver Disease Questionnaire for Non-Alcoholic Steatohepatitis in Patients with Biopsy-Proven Non-alcoholic Steatohepatitis. ( 30639779 )
2019
31
International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. ( 30153225 )
2019
32
Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. ( 30257063 )
2019
33
Primary hepatic marginal B cell lymphoma of mucosa-associated lymphoid tissue (MALT) and non-alcoholic steatohepatitis (NASH): more than a coincidence? ( 30488325 )
2019
34
HSPA12A Is a Novel Player in Nonalcoholic Steatohepatitis via Promoting Nuclear PKM2-Mediated M1 Macrophage Polarization. ( 30455376 )
2019
35
Nonalcoholic Steatohepatitis Is Becoming a Top Indication for Liver Transplantation Worldwide. ( 30472779 )
2019
36
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. ( 30511198 )
2019
37
Blackcurrant (Ribes nigrum) Prevents Obesity-Induced Nonalcoholic Steatohepatitis in Mice. ( 30569636 )
2019
38
High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population. ( 30608932 )
2019
39
Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. ( 30609187 )
2019
40
A cut-off value of shear wave speed to distinguish nonalcoholic steatohepatitis candidates. ( 30633176 )
2019
41
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. ( 30653691 )
2019
42
Predicting Outcomes of Liver Transplantation in Patients With Nonalcoholic Steatohepatitis: Pretransplant Renal Function Is Key. ( 30657244 )
2019
43
Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. ( 30658094 )
2019
44
Pilot Study to Diagnose Nonalcoholic Steatohepatitis With Dynamic 18F-FDG PET. ( 30673340 )
2019
45
Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity. ( 30684890 )
2019
46
Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. ( 30700851 )
2019
47
F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice. ( 30703849 )
2019
48
Effects of duodenal-jejunal bypass surgery in ameliorating nonalcoholic steatohepatitis in diet-induced obese rats. ( 30705600 )
2019
49
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis. ( 30707282 )
2019
50
Comprehensive circular RNA expression profiles in a mouse model of nonalcoholic steatohepatitis. ( 30720095 )
2019

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

Pathways related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.21 ADIPOQ CYP2E1 INS LEP PPARA TNF
2
Show member pathways
13.09 ADIPOQ INS KRT18 LEP PPARA TNF
3
Show member pathways
12.58 ADIPOQ LEP PPARA TNF
4
Show member pathways
12.41 ADIPOQ INS LEP TNF
6
Show member pathways
11.54 INS PPARA TNF
7
Show member pathways
11.42 ADIPOQ INS TNF
8 11.22 ADIPOQ INS LEP PNPLA3 PPARA TNF
9 11.1 ADIPOQ LEP PPARA TNF
10 11.07 CYP2E1 PPARA
11 10.85 ADIPOQ LEP
12 10.67 ADIPOQ LEP TNF
13 10.57 GPT INS

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 ADIPOQ GPT HFE INS LEP TNF

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.9 ADIPOQ INS LEP TNF
2 positive regulation of protein phosphorylation GO:0001934 9.79 ADIPOQ SQSTM1 TNF
3 response to hypoxia GO:0001666 9.79 ADIPOQ LEP PPARA
4 positive regulation of protein kinase B signaling GO:0051897 9.78 INS LEP TNF
5 response to ethanol GO:0045471 9.67 ADIPOQ CYP2E1 LEP
6 acute-phase response GO:0006953 9.65 HFE INS
7 glucose homeostasis GO:0042593 9.65 ADIPOQ INS LEP
8 positive regulation of glucose import GO:0046326 9.64 ADIPOQ INS
9 negative regulation of blood pressure GO:0045776 9.64 ADIPOQ PPARA
10 positive regulation of cytokine production GO:0001819 9.63 LEP TNF
11 positive regulation of cytokine secretion GO:0050715 9.63 INS TNF
12 response to bacterium GO:0009617 9.63 ADIPOQ CYP2E1 SLC17A5
13 positive regulation of interleukin-8 production GO:0032757 9.62 ADIPOQ TNF
14 leukocyte tethering or rolling GO:0050901 9.59 LEP TNF
15 positive regulation of long-term synaptic potentiation GO:1900273 9.58 INS SQSTM1
16 negative regulation of lipid catabolic process GO:0050995 9.58 INS TNF
17 positive regulation of cellular protein metabolic process GO:0032270 9.57 ADIPOQ INS
18 positive regulation of insulin receptor signaling pathway GO:0046628 9.56 INS LEP
19 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.55 SQSTM1 TNF
20 negative regulation of gluconeogenesis GO:0045721 9.54 ADIPOQ INS
21 negative regulation of glucose import GO:0046325 9.52 LEP TNF
22 negative regulation of growth of symbiont in host GO:0044130 9.51 SQSTM1 TNF
23 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.43 ADIPOQ PPARA
24 regulation of protein secretion GO:0050708 9.4 INS TNF
25 negative regulation of appetite GO:0032099 9.37 LEP PPARA
26 negative regulation of lipid storage GO:0010888 9.32 LEP TNF
27 positive regulation of peptide hormone secretion GO:0090277 9.26 HFE INS
28 negative regulation of receptor binding GO:1900121 9.16 ADIPOQ HFE
29 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.13 INS LEP TNF
30 glucose metabolic process GO:0006006 8.92 ADIPOQ INS LEP TNF

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....